Atara Biotherapeutics (NASDAQ:ATRA) Given Neutral Rating at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Atara Biotherapeutics (NASDAQ:ATRA – Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. HC Wainwright also issued estimates for Atara Biotherapeutics’ Q2 2024 earnings at $0.06 EPS, Q3 2024 earnings at ($0.28) EPS, Q4 2024 earnings at ($0.28) EPS, FY2024 earnings […]

Related Keywords

United States ,Anhco Nguyen ,Pascal Touchon ,Harbor Capital Advisors Inc ,Atara Biotherapeutics Inc ,Vontobel Holding Ltd ,Advisor Group ,Josh Arnold Investment Consultant ,Atara Biotherapeutics Company Profile ,Delap Wealth Advisory ,Free Report ,Get Free Report ,Wealth Advisory ,Arnold Investment Consultant ,Harbor Capital Advisors ,Capital Advisors ,